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Abstract
Background: An intractable plantar keratoma (IPK) is a conical thickening of the epidermis’ stratum corneum and a
common cause of foot pain which can have a significant, detrimental impact on the mobility, quality of life and
independence of individuals. Conservative treatments are currently offered to patients with IPK, but they are
unsatisfactory since they do not offer a sufficient or permanent reduction of symptoms. The purpose of this study
was the evaluation of the feasibility, safety and effectiveness of innovative treatments for intractable plantar
keratoma (IPK).
Methods: A randomized single blind trial with 40 patients divided with block randomization in four parallel groups
was conducted to compare treatment combinations: conservative sharp debridement only or sharp debridement
with needle insertion, physiological water injection or lidocaine injection. All patients obtained the same treatment
four times at a four-week interval. At each visit, visual analog scale (VAS), Foot Function Index (FFI) and IPK size
were evaluated. VAS and FFI were also completed at a six and twelve-month follow-up.
Results: Our findings in regards to feasibility demonstrated recruitment challenges because of the anticipated pain
that would be provoked by needle insertion may not be worth the potential pain relief compared to debridement
alone from the patient’s perspective. This was also the principal cause of drop out. Our preliminary results show no
main effect of group for any of the clinical outcomes: pain felt on VAS, FFI score, IPK’s size (p > 0.05). However, the
analysis revealed a statistically significant effect of time on VAS (p < 0.001), FFI score (p < 0.001) and IPK’s size (width
and depth (p < 0.001); length (p = 0.001)), but no group x time interaction was found (p > 0.05).
Conclusions: This study demonstrates that IPK treatment consisting of sharp debridement with needle insertion,
physiological saline water injection or lidocaine injection is feasible and safe. There was a non-statistically significant
trend toward diminishing pain intensity compared to scalpel debridement alone. The pain provoked by needle
insertion and injection treatments must be addressed with a scientifically proven protocol to make it more
comfortable for patients before these treatments could be considered in further studies.
Trial registration: ClinicalTrials.gov, NCT04777227. 2 March, 2021 - Retrospectively registered (All participants were
recruited prior to registration).
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Background
Callosities are a common cause of foot pain which
can have a significant, detrimental impact on the
mobility, quality of life and independence of individ-
uals [1–5]. A common lesion in the callosities’ family
is the intractable plantar keratoma (IPK). The IPK is
a dermatologic painful lesion which consist in a con-
ical thickening of the epidermis’ stratum corneum
[6] on the plantar aspect of the foot [6]. This derma-
tological condition has a prevalence between 51 and
68% among people aged 65 and over and is a fre-
quent consultation reason in medical clinics [7]. The
elderly population is more susceptible to callosities
because the loss of soft tissue is part of the aging
process and atrophy of the plantar fat pad increase
the plantar pressure, the pain and it limits ambula-
tion [8–10]. The onset of this lesion can rarely be
secondary to a genetic deficiency but is, in most
cases, due to repetitive trauma caused by major
pressure or friction points [6, 11, 12]. As an out-
come of trauma, corneocytes which are terminally
differentiated keratinocytes, have a higher speed of
differentiation which leads to an incomplete differen-
tiation [13]. This maintains the cells in contact with
each other and preclude their desquamation from
the epidermis, which causes callus accumulation and
creates an IPK [14]. IPKs are mostly found in
women, in people who spend long hours standing
and in people having foot deformities that modify
pressure points like bunions and hammer toes [3].
Despite the different types of treatment currently
available for IPKs (keratolytic ointments, partial off-
loading with orthotic devices, insoles, paddings and
therapeutic shoes, moisturizers and emollients,
bleomycin sulfate or hyaluronic acid or silicone in-
jections), the treatment of choice is scalpel debride-
ment alone [4, 15–25]. Conservative treatment are
currently offered to patients with IPK, but they are
unsatisfactory since they do not offer a sufficient or
permanent reduction of symptoms [26, 27]. If con-
servative treatments fail, surgical treatments such as
arthroplasty, bunionectomy, osteotomy, skin flap and
punch biopsy are offered [21, 27–29]. However, it
has been reported that IPK’s surgical management
can lead to transfer lesions because plantar pressure
points are relocated [27, 28].
Evidence is scarce especially for IPKs management in
the literature even if it is a widespread painful problem.
A previous study at our institution compared the effect
on pain relief and functional capacity of a subcutaneous
injection of physiological saline water (PSW) compared
to a subcutaneous injection of hyaluronic acid (HA)
under a debrided IPK [20]. Considering this previous
work, efforts are done to find innovative treatments for
those who are suffering of an IPK. Therefore, the first
objective of this study was to determine the feasibility
and safety of four different treatments for painful IPK
with scalpel debridement: alone, combined with needle
insertion or a subcutaneous injection of PSW or a
subcutaneous injection of lidocaine solution (LS). The
second objective was to obtain preliminary result con-
cerning the short and long term efficacity of these treat-
ments on pain intensity scores. We hypothesize that
treatments by needle insertion, PSW injection or LS
injection of IPKs are feasible and safe and may show
improvement of the IPK lesion on short and long term
better than the debridement alone.
Method
Data source, recruitment and sample
This single blind feasibility study focused on safety
and outcomes of an injection therapy for IPKs and
was conducted in a private podiatric medicine clinic
(Clinique Podiatres Plus) located in Quebec City and
at the University of Québec at Trois-Rivières podia-
try teaching clinic, in the province of Quebec,
Canada. The study protocol was approved by the in-
stitutional ethical committee (UQTR CER-15-214-
07.17). Initial protocol was amended in order to im-
prove enrollment rate with use of publicity in local
newspaper and add an additional recruitment clinical
site (Clinique Podiatres Plus). Initial recruitment was
realized by the professionals and the students in
both settings as well as through a local newspaper
advertisement. A total of 63 patients were
approached to join the study. Forty patients met in-
clusion criteria which were verified by the principal
investigator (MPM). Selection questionnaire is avail-
able in Additional file 1. All patients signed an in-
formed consent form before their enrollment. The
study was conducted on a 39-month period, between
June 2015 to September 2019. Inclusion and exclu-
sion criteria are listed in Table 1. Enrolled patients
were informed that all treatments were free of cost,
and if an intervention was significatively more effect-
ive, they would be offered this treatment at the end
of the trial. A flow diagram summarizes patients’
distribution in Fig. 1. No minimal sample size calcu-
lation was done because of the nature of the study
but a threshold between 40 to 60 patients was tar-
geted according to the previous work on sample size
for feasibility study that suggest a range of 10 to 300
participants with a median of 38 [30].
Randomization and blinding
Treatment allocation was made by block randomization
for four parallel groups following a computer-generated
list of random numbers (allocation ratio 1:1:1:1).
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Patients were assigned to a number in order of
subscription. Patients were blinded to their treatment
regimen during the whole study. Only independent re-
search assistants had access to this list to prepare the
treatment material in a covered container to avoid
any bias during evaluation. The container was open
once the podiatrist (MPM) had completed the
physical evaluation and had confirmed a clinical IPK
diagnosis [6]. All syringes were covered with medical
tape (Hypafix, BSN) to mask their content.
Intervention description
Once the clinical diagnosis was confirmed, IPK debride-
ment was completed using a scalpel and number 15 blade,
a podiatry drill and a spherical podiatry burr. In case of
multiple IPKs, the patient chose the most painful lesion to
be considered for the trial. IPK’s length and width was
measured with a millimeter scale ruler used in wound care
(accuracy ± 0.1mm). The depth was estimated with a
cotton tip applicator technique measured with the same
ruler [31]. If the patient was assigned to receive needle
insertion or injection, a 27 gauge needle on a 3mL syringe
was inserted at 10 to 15 degrees with the bevel facing up
approaching from the IPK’s right side. If the syringe’s piston
was raised, the podiatrist pressed completely on it to inject
1mL of the liquid without knowing its nature being either
0.9% sterile sodium chloride water or 2% (20mg/ml) lido-
caine solution (Aspen Pharma, Canada). IPK was then ban-
daged with a sterile gauze and medical tape (Hypafix, BSN
medical). The patient was instructed to keep the dressing
dry for 24 h before its removal. Patient were also advised to
avoid any kind of treatment for their IPK between trial in-
terventions. At each intervention, the podiatrist asked the
patient if he or she received another treatment since the last
visit. IPK photo was taken at each step of the intervention
(before and after debridement and after the intervention).
Photos of one patient are presented in Additional file 2 as
an example. Each group was planned to receive four times
the same intervention at a 4-week interval. A telephone
follow-up was made at 6months and 12months after the
first intervention.
Fig. 1 Patient flow diagram
Table 1 Inclusion and exclusion criteria
Inclusion criteria
• ≥ 18 years old
• Having a painful IPK for at least 3 months
Exclusion criteria
• Ongoing pregnancy or breastfeeding
• Severe cardiovascular or neurological disease
• Immunosuppressed status
• Presence of a plantar ulcer
• Allergy to lidocaine
• History of keloid or hypertrophic scar
• Simultaneous painful plantar syndrome unrelated to the presence
of an IPK
Group 1: Scalpel debridement only.
Group 2: Scalpel debridement with needle insertion.
Group 3: Scalpel debridement with subcutaneous injection of physiological
saline water.
Group 4: Scalpel debridement with subcutaneous injection of lidocaine
solution 2%
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Data collection and outcomes measures
A questionnaire presented in Additional file 3 was per-
formed at the first visit to collect baseline characteristics
(e.g. demographic data, treatments already tried includ-
ing frequency and effectiveness) by the podiatrist. These
data were collected to compare our sample with the gen-
eral population with IPKs. At each intervention (T2, T3
and T4), patients were asked by the research assistant to
rate their pain level during the seven previous days on
the visual analogue scale (VAS) [32]. The VAS is a 10
cm line anchored at the beginning by “no pain” and at
the end by “worst pain imaginable”. The patient had to
place a vertical mark on the scale to indicate his pain in-
tensity level. VAS score is established by measuring the
distance in centimeters (0 to 10) from the “no pain” an-
chor point [32]. Patients had to complete the validated
foot pain questionnaire translated into French and short-
ened to 27 questions, the Foot-Function-Index-Revised
(FFI-R) [33, 34]. The FFI-R is presented in Additional
file 4. In order to make sure that the protocol was safe
for patients according to CONSORT extension for
harms and adverse events, the podiatrist ask if the pa-
tient had any adverse effects or complications secondary
to last treatment [35]. The podiatrist was not allowed to
ask patients about IPK’s symptoms and function during
visits. A telephone follow-up was made 6 and 12months
after the first intervention (baseline) in order to
complete the same questionnaire answered during the
first visit (Additional file 2), VAS (pain level during the
seven previous days) and FFI-R questionnaire
(Additional file 4). Data collection at 6 and 12months
was completed with three additional questions about
pain perceived during the experimental interventions as
presented in Additional file 5.
Statistical analysis
All non-parametric values (baseline characteristics) have
been subjected to a chi-squared test. Pain intensity
(VAS) and FFI-R scores were independently subjected to
a repeated-measures analysis of variance (ANOVA x r)
having four levels of group (scalpel debridement alone
(group 1), scalpel debridement combined with needle in-
sertion (group 2), scalpel debridement combined with
subcutaneous injection of PSW (group 3) or scalpel de-
bridement combined with subcutaneous injection of LS
(group 4)) and five levels of time of measurements (base-
line intervention, second intervention (T2), third inter-
vention (T3), fourth intervention (T4), and 6-month
(T6) and 12-month (T12) follow-ups). Statistical signifi-
cance was set, for all analyses, at p value ≤0.05. All ana-
lyses were performed using Statistica (version 13;
StatSoft; Oklahoma, United States) and Excel (version
16; Microsoft Corporation; Washington, United Stated).
Finally, we did an intention-to-treat analysis since
missing data by dropped-out patients were replaced by
the last value available. Feasibility data are reported with
descriptive statistics in a narrative synthesis. Finally, this
feasibility study is reported using CONSORT extension
for pilot and feasibility trials checklist [36]. The study
protocol was retrospectively registered on Open Science




As showed in Fig. 1, 40 patients were recruited over a
two-year period in the two clinical settings. Recruitment
was stopped because four equal randomized groups of
10 patients were enrolled. The same podiatrist (MPM)
provided all 154 interventions and placed all follow-up
phone calls at T6 and T12. Ninety percent of patients
(n = 36) attended all four prescribed interventions and
completed the 6-month follow-up. However, only 67.5%
(n = 27) completed the 12-month follow-up. Several at-
tempts had been made by the podiatrist to reach patients
by phone, but efforts remained unfruitful to collect
follow-up data in some cases. Throughout the protocol,
the major reason for dropout was anticipated pain that
would be provoked by the injection. At the 6-month
follow-up phone call, 12.5% of group 2, 30% of group 3
and 14.3% of groups 4 patients said that the effectiveness
of the treatments was not worth the pain felt during the
interventions. The pain was felt during the needle inser-
tion or the injection. Furthermore, some patients still
had discomfort few days after the intervention. No pa-
tient in the group 1 reported pain secondary to the
intervention (debridement only). Except for pain, no pa-
tient reported any other side effects for the duration of
the feasibility study related to the intervention.
Safety
Only pain at the injection site for a few hours have been
stated by a limited number of patients. No other adverse
effect has happened.
Group comparisons
Patient baseline characteristics are presented in the
Table 2. There was no statistically significant difference
between groups (p > 0.05). They were equivalent for age,
time since apparition of IPK, time before first consult-
ation, time spent standing up per day and daily cigarette
smoking. Women represented 57.5% (23/40) of all pa-
tients. IPKs selected for study intervention were located
under a metatarsal head, the styloid process of the fifth
metatarsal and the heel respectively for 87.5% (34/40),
7.5% (3/40) and 5% (2/40). Thirty-five percent (14/40) of
patients wore plantar orthoses on a daily basis and
37.5% (15/40) had at least one foot deformity. It was
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observed by the podiatrist during the first evaluation
(baseline) that 11 of the 14 smokers (78.5%) and 4 of the
22 non-smokers (18%) presented macerated skin around
the selected. Based on patient self-reporting data, none
received another intervention than what was provided
during the trial.
Clinical outcomes
Clinical outcomes data are detailed in Table 3. After
analysis, there were no statistically significant difference
between groups for any clinical outcomes: VAS pain
score (F [3, 36] = 1.45, p = 0.26), FFI-R score (F [3, 36] =
0.85, p = 0.33), IPK’s width (F(3,36) = 0.55, p = 0.65),
IPK’s length (F [3, 36] = 0.36, p = 0.78) and IPK’s depth
(F [3, 36] = 1.25, p = 0.31). However, analysis revealed an
effect of time on VAS (F [4, 48] = 18.03, p < 0.001), FFI-
R score (F [4, 48] = 17.85, p < 0.001), IPK’s width (F [3,
36] = 12.74, p < 0.001), IPK’s length (F [3, 36] = 5.93,
p = 0.001) and IPK’s depth (F [3, 36] = 51.94, p < 0.001).
Trends for outcomes measures VAS and FFI-R are pre-
sented in Fig. 2. Similarly, no statistically significant
Group x Time interaction was found on VAS (F(12,
144) = 1.12, p = 0.83), FFI-R score (F(12,144) = 0.93, p =
0.35), IPK’s width (F(9,108) = 1.40, p = 0.20), IPK’s length
(F(9,108) = 1.27, p = 0.26) and IPK’s depth (F(9,108) =
1.41, p = 0.19).
Discussion
The objectives of this study were to determine feasi-
bility, safety and gather preliminary outcomes in re-
lation with four IPK treatment combinations,
including scalpel debridement alone, scalpel debride-
ment combined with needle insertion, scalpel de-
bridement combined with subcutaneous injection of
PSW or scalpel debridement combined with
subcutaneous injection of LS. This study was con-
ducted to explore new treatments for IPK. Regarding
feasibility, the main comment from groups 2, 3 and
4 patients was that pain felt during the intervention
was important and that it was not worth treatment’s
overall efficacy. This was stated by more that 55% of
the patients respectively at 6 and 12-month follow-
ups. To avoid this situation, an anesthetic block of
the tibialis nerve could have been performed before
the needle insertion and injection, but callus treat-
ment does not represent a current indication for this
procedure [37]. Furthermore, the fact that twice the
proportion of patients in group 3, whom received a
saline water injection, had more pain than patients
in group 4, whom received a LS injection, might
possibly be explained by the anesthetic property of
lidocaine [38]. This should be investigated in a
future study.
The treatment combinations have been determined by a
literature review, previous work and hypotheses [20, 39].
Many aspects of those combinations could explain the time
effect observed in this study. In ascending order, intrader-
mic needle insertion, PSW and LS injection all increase
local blood flow [40, 41]. Furthermore, microneedling,
which consists in needle insertion in scar or tendon, has
been shown effective in diminishing acne scar and in
treatment of Achilles tendinitis and lateral epicondyloses
[42, 43]. This technique creates micro-wounds, restarts
normal healing process and stimulates collagen and elastin
production, which are important components of skin struc-
ture. Furthermore, lidocaine has a negative effect on fibro-
blast proliferation in cell culture medium [44, 45]. The
fibroblasts are dermal cells that continually interact with
keratinocytes through growth factors and dictate their pro-
liferation rate [46]. These effects have been observed at
Table 2 Patients’ baseline characteristics









Age in years, Mean (SD) 59.7 (18.8) 60.1 (14.8) 61.6 (14.4) 50.3 (17.7) 0.4
Sex ratio, M:W 6:4 3:7 4:6 4:6 –
Time since IPK apparition in months, Mean (SD) 213.0 (228.3) 192.6 (140.9) 132.0 (74.7) 62.8 (69.2) 0.1
Time before first consultation in weeks, Mean (SD) 439.4 (602.4) 153.4 (198.6) 242.0 (503.5) 119.2 (201.2) 0.3
Time spent standing hours/day, Mean (SD) 6.5 (2.9) 6.0 (2.3) 7.9 (3.2) 6.9 (3.2) 0.5
Debridement frequency before study in days, Mean (SD) 100.9 (102.2) 142.8 (134.4) 98.9 (29.0) 91.3 (38.3) 0.6
Smoking (n) 6 2 2 4 0.2
Plantar orthoses worn daily (n) 5 3 4 2 0.5
Macerated IPK at first visit (n) 6 3 3 3 0.4
Presence of foot deformity (n) 3 6 4 2 0.3
IPK location ratio, Met:H:S 10:0:0 10:0:0 7:2:1 7:0:2 –
a P-value calculated with the chi-squared test
SD standard deviation; M men; W women; IPK intractable plantar keratoma; Met under metatarsal head; H under the heal; S under styloid process of the 5th
metatarsal; n number
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clinically-used concentrations [44, 47]. Finally, lidocaine
modifies granulocytes cellular membrane [48, 49]. Since the
membranes are modified, these cells can no longer adhere
to surfaces, which prevents them from releasing inflamma-
tory factors [49]. This interesting property of lidocaine
could therefore possibly reduce the pain associated with
IPKs. However, those explanations are hypotheses, and
histopathological and biochemistry analyses could have
been relevant but are challenging and not a part of an IPK
clinical treatment goals.
The VAS and the IPK measurements taken at each
follow-up interventions furthermore show a downward
trend in patients who received an injection (either group
3 or 4) compared with the other groups. The FFI-R
score demonstrated a higher tendency to produce low
scores with the PSW and LS injection interventions.
Also, patients who had scalpel debridement only re-
ported higher mean of VAS, FFI-R score and IPK mea-
surements. Those results are not statistically significant,
but this can possibly be explained by the small number
of patients in each group. It is also important to note
the shorter interval of time between treatments planned
during the experimental protocol in comparison with
what the patients where used to before this study. In
fact, during the study all patients had a scalpel debride-
ment every 28 to 30 days, compared with reported previ-
ous debridement frequency at an average interval of
108.5 days all groups combined. The statistically signifi-
cant time effect could be explained by the fact that all
treatments were highly effective after the first interven-
tion and as a result of higher treatment frequency. The
shorter period of time between treatments leads to a de-
crease in hyperkeratosis’ accumulation. Since the accu-
mulation is less, this could explain the lower scores
obtained on VAS and FFI-R. These results cannot be
directly compared with other studies on the subject as
this project is the first one comparing all treatment com-
binations with scalpel debridement alone for IPKs.
Table 3 Clinical outcomes data by group
Group 1 Group 2 Group 3 Group 4
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
n = 10 at baseline n = 10 at baseline n = 10 at baseline n = 10 at baseline
VAS Baseline 4.8 (2.1) 3.7 (2.0) 4.2 (2.9) 3.5 (3.0)
(0–10) T2 1.9 (2.6) 1.7 (2.3) 1.0 (1.6) 1.7 (2.3)
T3 2.6 (3.0) 1.2 (2.1) 0.7 (1.3) 1.2 (2.3)
T4 2.8 (3.0) 0.2 (0.3) 0.6 (1.4) 1.2 (2.3)
T6 4.0 (3.6) 3.1 (3.0) 2.2 (3.1) 1.2 (2.3)
T12 5.3 (3.7) 1.8 (2.7) 2.2 (2.4) 2.7 (2.8)
FFI-R Baseline 68.8 (17.1) 57.8 (29.4) 69.6 (34.7) 53.4 (29.6)
(/270) T2 45.1 (20.9) 45.1 (26.2) 37.3 (25.8) 37.1 (22.9)
T3 51.1 (37.1) 30.1 (11.7) 32.4 (22.6) 32.6 (23.4)
T4 41.2 (23.7) 28.5 (13.7) 31.1 (24.8) 32.5 (23.4)
T6 54.1 (41.9) 34.4 (21.9) 46.3 (42.4) 31.9 (23.6)
T12 63.5 (48.5) 37.7 (22.9) 33.3 (14.0) 34.4 (22.7)
IPK’s Width Baseline 3.4 (1.6) 3.3 (2.7) 3.1 (1.6) 2.0 (1.5)
(mm) T2 2.8 (0.9) 2.1 (1.3) 2.8 (2.6) 2.1 (0.9)
T3 2.1 (0.9) 1.7 (1.5) 2.5 (3.4) 1.4 (1.4)
T4 2.1 (1.4) 1.9 (1.6) 0.9 (1.1) 1.4 (1.4)
IPK’s Length Baseline 2.7 (1.0) 2.9 (2.7) 3.4 (2.2) 2.5 (1.5)
(mm) T2 2.7 (1.0) 2.1 (1.6) 2.8 (2.6) 2.1 (1.2)
T3 2.5 (1.1) 1.9 (1.4) 3.0 (4.1) 1.6 (1.6)
T4 2.3 (1.5) 1.8 (1.4) 1.1 (1.5) 1.6 (1.6)
IPK’s Depth Baseline 1.7 (0.7) 1.7 (0.8) 1.7 (0.6) 1.5 (0.9)
(mm) T2 1.4 (0.5) 1.1 (0.9) 0.8 (0.4) 1.0 (0.7)
T3 0.9 (0.1) 0.8 (0.7) 0.3 (0.3) 0.7 (0.8)
T4 1.0 (0.7) 0.8 (0.6) 0.3 (0.4) 0.7 (0.8)
VAS Visual analog scale; FFI-R Foot Function Index-Revised; IPK Intractable Plantar Keratoma; SD Standard Deviation; mm: millimeter; T2 intervention at 4-week; T3
intervention at 8-week; T4 intervention at 12-week; T6 6-month follow-up; T12 12-month follow-up
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However, pain alleviation after callus debridement in-
cluding IPK, is reported for short and medium terms
and are consistent with our results [15, 23, 50].
Strengths and limitations
The strength of this study is its innovative quality as it
explores potential IPKs treatments that could be long-
lasting and its contribution to raise new hypotheses for
people who suffer from this prevalent foot health prob-
lem [51]. Regarding efficacy, the limited number of pa-
tients included limits results interpretation. However,
this feasibility study provided information about recruit-
ment, retention, randomization and treatment fidelity
[51]. The recruitment was not as easy and fast as antici-
pated. This can be explained by the nature of the experi-
mental treatment and this knowledge could help
Fig. 2 a VAS scores and b FFI-R mean scores, at baseline, after 4 weeks (T2), 8 weeks (T3), 12 weeks (T4) and at 6 (T6) and 12-month (T12) follow-
ups. Standard deviations are represented in box plots. Trendlines associated with each group are represented as dashed lines
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planning for future studies on IPK treatment with injec-
tion. For some patients, the use of a needle can be a
major barrier to treatment and seems too invasive for
how they perceive their condition [52]. Even though the
recruitment was conducted on a two-year period, only
40 patients were recruited. Initially, the ideal target was
60 (15 patients per groups). Another reason justifying re-
cruitment difficulties is the fact that for some individ-
uals, the initial foot pain and limitations were low so the
pain anticipated from the needle insertion and injection
may not be worth the potential pain relief compared to
debridement alone. In addition, the pain felt during
intervention with needle insertion played a role in pa-
tient retention. The randomization was feasible, but it
was not possible to blind (patient and podiatrist) of the
group 1 (debridement only) comparing to the three
other groups. In this study, the evaluator and the
performer were the same person which can lead to
performance bias. However, to limit this risk of bias, the
treatment containers were always covered during the
evaluation before the experimental treatment was
provided to the patient. The syringes content was also
masked by an assistant. Even if 4 weeks separated each
treatment, it would have been possible to remember if
the patient received scalpel debridement only or another
treatment because of the small sample size. Finally, the
ruler that measured IPK’s length, width and depth could
lead to an increased measurement uncertainty and lack
of repeatability. The use of a digital caliper could have
help but the depth measurement would have still been a
challenge. In a further study, a more efficient tool is
needed to analyse continuous variable like IPK’s size or
this outcome could be addressed as a dichotomous vari-
able like IPK cured or not. Overall, there are remaining
uncertainties about the feasibility to use PWS and LS in-
jections for IPK treatment.
In conclusion, the treatment by needle insertion,
PSW injection or LS injection of painful IPKs is
feasible and safe. Findings has demonstrated a trend
towards diminished pain intensity on VAS and FFI-R
compared to scalpel debridement alone. On the
other hand, despite this observed trend, there was
no statistically significant difference in the final
scores (VAS and FFI-R) between all groups. Further
research with strongest design including more pa-
tients need to be done before considering the use of
an injection therapy for painful IPKs.
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